BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1262@pharmaconomics
DTSTAMP:20260707T051238Z
DTSTART;VALUE=DATE:20240101
DTEND;VALUE=DATE:20240102
SUMMARY:MOLN Phase 1 — MP0317
DESCRIPTION:Phase 1 trial results for MP0317 in advanced cancer types are due Jan 1\, 2024. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1745114/000117184326002920/exh_991.htm\n\nTrack it: https://www.pharmaconomics.com/e/1262
URL:https://www.pharmaconomics.com/e/1262
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:MOLN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR